Logo

American Heart Association

  27
  0


Final ID:

Debate- Colchicine for ASCVD: A Game-Changer or a Niche Therapy? Colchicine – ready for prime time

  • Mehta, Anurag  ( Virginia Commonwealth University , Glen Allen , Virginia , United States )
  • Blaha, Michael  ( JOHNS HOPKINS HOSPITAL , Baltimore , Maryland , United States )
  • Budoff, Matthew  ( LUNDQUIST INSTITUTE , Torrance , California , United States )
  • Author Disclosures:
    Anurag Mehta: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Active (exists now) | Michael Blaha: DO have relevant financial relationships ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Consultant:Eli Lilly:Past (completed) ; Consultant:Boehringer Ingelheim:Past (completed) ; Consultant:Astra Zeneca:Past (completed) ; Consultant:New Amsterdam:Active (exists now) ; Consultant:Agepha:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Idorsia:Past (completed) ; Consultant:Genentech:Past (completed) ; Consultant:Bayer:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Bayer:Active (exists now) | Matthew Budoff: DO have relevant financial relationships ; Researcher:Lilly:Active (exists now) ; Speaker:Boehringer-Ingleheim:Active (exists now) ; Speaker:Lilly:Active (exists now) ; Speaker:Novo Nordisk:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Researcher:Amgen:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Inflammation and Atherosclerosis: Smoldering Threat or Therapeutic Target?

Saturday, 11/08/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

You have to be authorized to contact abstract author. Please, Login
Not Available